Lonza (LONN.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

LONN.SW · Stock Price

CHF 486.20-85.00 (-14.88%)

Market Cap: $43.5B

Historical price data

Overview

Lonza is the global leader in the CDMO sector, operating a mission-critical, capital-light business model that enables pharmaceutical and biotech clients to outsource complex development and manufacturing. Its strategic achievement lies in building an unparalleled, multi-modal technology platform spanning advanced biologics, cell and gene therapies, and small molecules, making it a partner of choice for the industry's most innovative modalities. The company's strategy focuses on capacity expansion in high-growth areas, technological leadership, and deep customer partnerships to capitalize on the secular trend of outsourcing in life sciences.

AntibodiesBiologicsSmall Molecules

Technology Platform

Integrated multi-modal CDMO platform encompassing proprietary mammalian cell line systems (GS Xceed®), viral vector and cell therapy manufacturing, lipid nanoparticle (LNP) formulation, and complex small molecule synthesis.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamid...	Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1

Funding History

1

IPOUndisclosedUndisclosedJun 15, 1999

Opportunities

Lonza is poised to capture outsized growth from the structural increase in biopharma outsourcing, particularly for complex modalities like cell & gene therapies and mRNA/LNPs where it holds first-mover advantages.

Its global capacity expansion and technological investments directly align with the industry's most pressing needs for scalable, advanced manufacturing.

Risk Factors

Key risks include execution challenges in its significant global capacity build-out, potential pricing pressure from competitors, and reliance on the success and funding health of its biotech and pharma client base.

Technological disruption and geopolitical supply chain issues also pose long-term challenges.

Competitive Landscape

Lonza competes with large full-service CDMOs like Catalent and Samsung Biologics, specialized players like WuXi Biologics, and CGT-focused firms. Its competitive moat is built on proprietary technology platforms (GS Xceed®, Cocoon®), unmatched multi-modal integration, a global scale, and a century-long reputation for quality and neutrality.

More companies in Biologics / Biosimilars →More companies in Switzerland →